anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-03. Numbers and descriptions here follow the published literature rather than marketing material.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Side effects of fentanyl analogues are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Illicitly used fentanyl analogues have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
Progesterone is a progestogen, or an agonist of the nuclear progesterone receptors (PRs), the PR-A, PR-B, and PR-C. In one study, progesterone showed EC50Tooltip half-maximal effective concentration values of 7.7 nM for the human PR-A and 8.0 nM for the human PR-B. In addition to the PRs, progesterone is an agonist of the membrane progesterone receptors (mPRs), including the mPRα, mPRβ, mPRγ, mPRδ, and mPRϵ. It is also a potent antimineralocorticoid (antagonist of the mineralocorticoid receptor (MR)), as well as a very weak glucocorticoid (agonist of the glucocorticoid receptor). Progesterone does not interact significantly with the androgen receptor (AR) or with the estrogen receptor (ER). In addition to its activity as a steroid hormone, progesterone is a neurosteroid. Specifically, it is an antagonist of the sigma σ1 receptor, a negative allosteric modulator of nicotinic acetylcholine receptors, and, via its active metabolites allopregnanolone and pregnanolone, a potent positive allosteric modulator of the GABAA receptor, the major signaling receptor of the inhibitory neurotransmitter γ-aminobutyric acid (GABA).
=== Riken === While the JINR–LLNL collaboration had been studying fusion reactions with 48Ca, a team of Japanese scientists at the Riken Nishina Center for Accelerator-Based Science in Wakō, Japan, led by Kōsuke Morita had been studying cold fusion reactions. Morita had previously studied the synthesis of superheavy elements at the JINR before starting his own team at Riken. In 2001, his team confirmed the GSI's discoveries of elements 108, 110, 111, and 112. They then made a new attempt on element 113, using the same 209Bi + 70Zn reaction that the GSI had attempted unsuccessfully in 1998. Despite the much lower yield expected than for the JINR's hot fusion technique with calcium-48, the Riken team chose to use cold fusion as the synthesised isotopes would alpha decay to known daughter nuclides and make the discovery much more certain, and would not require the use of radioactive targets. In particular, the isotope 278113 expected to be produced in this reaction would decay to the known 266Bh, which had been synthesised in 2000 by a team at the Lawrence Berkeley National Laboratory (LBNL) in Berkeley. The bombardment of 209Bi with 70Zn at Riken began in September 2003. The team detected a single atom of 278113 in July 2004 and published their results that September:
==== Zebrafish ==== Being model organisms, zebrafish myomeres have been extensively studied. The tail-bending maneuver generated by myomeres in zebrafish requires innervation from motor neurons for both the hypaxial and epaxial muscle regions. It has been found that timing/intensity of neurons firing in these two regions varies, respectively. This process is mediated by a circuit that controls motor neuron activation during swimming behaviors, which, in turn, affects force generation. Similar to this idea, one study found that hypaxial and epaxial myomere activation did not always correlate with myomeric fibers closer to the horizontal septum itself.
Sources: en.wikipedia.org
Sunday, February 27, 1955, began with some delegations on a tour of Morro Castle. After this, a parade proceeded down Avenida Carlos III from Infanta Street to Belascoaín. 40,000 people from Havana lined the streets to watch the parade go by. A grandstand reserved for visiting Freemasons with seating for 1,000 people was placed in front of the Masonic Temple. The flags of each country present were raised on flagpoles in front of the Masonic Temple. A rouse of applause was heard from the crowds of people in the street as they saw the flags raised. A large Cuban flag 30 meters (98 feet) long, gifted by the Cuban Young Hope Association (AJEF), was then unfurled and draped over the side of the Masonic Temple. The flag ceremonies were conducted by an Ajefista Commission of the AJEF. The consecration of the National Masonic Temple of the Grand Lodge of Cuba was overseen by Grand Master Carlos M. Piñeiro del Cueto and his secretariat. With a ribbon cutting, members of the public and Cuban Freemasons were allowed to see the building and walk around. The Freemasons moved into the High Chamber of the Grand Lodge, where the Third Inter-American Conference of Symbolic Freemasonry officially took place. Alejandro Poletti from the delegation of Mexico presided over the conference, but because of a recent accident he could not speak well. Alejandro Serani Burgos, from the Grand Lodge of Chile, spoke for some time, explaining more about the significance of the group of statues that the Chilean delegation had brought from Cuba, which were an exact replica of those located on the Alameda.
Injury in animals is damage to the body caused by wounding, change in pressure, heat or cold, chemical substances, venoms and biotoxins. Injury prompts an inflammatory response in many taxa of animals; this prompts wound healing, which may be rapid, as in the Cnidaria.
MTY Food Group is the parent company of 28 different franchising brands including Yogen Fruz Canada (operates locations as master franchisee), Mucho Burrito, Mr. Sub, Tiki Ming, Mrs. Vanelli's, Taco Time, Country Style, Thai Express, and Tandori. Founded by Stanley Ma, originally from Hong Kong, in 1979 when he opened his first restaurant Le Paradis du Pacifique in Montreal; the company incorporated in 1984 and joined the Toronto Stock Exchange in 2010. Most of the company's growth has come through acquisitions, but MTY has also launched at least 10 of the franchises. The 25-year-old company oversees 2251 (up from 1741 in 2010) quick service restaurants (excluding Mr. Sub locations, about 35 of MTY's locations are corporately run.) Its latest acquisitions are Jugo Juice and Groupe Valentine. System-wide sales increased 17.5% in 2010 while the number of locations rose by 57, or 10%.
According to the World Database on Protected Areas, 37% of Belize's land territory falls under some form of official protection, giving Belize one of the most extensive systems of terrestrial protected areas in the Americas. By contrast, Costa Rica only has 27% of its land territory protected. Around 20.4% of Belize's marine and coastal areas, which contain the Belize Barrier Reef, are protected. The Belize Barrier Reef is a UNESCO-recognized World Heritage Site and is the second-largest barrier reef in the world, behind Australia's Great Barrier Reef. A remote sensing study conducted by the Water Center for the Humid Tropics of Latin America and the Caribbean (CATHALAC) and NASA, in collaboration with the Forest Department and the Land Information Centre (LIC) of the government of Belize's Ministry of Natural Resources and the Environment (MNRE), and published in August 2010 revealed that Belize's forest cover in early 2010 was approximately 62.7%, down from 75.9% in late 1980. A similar study by Belize Tropical Forest Studies and Conservation International revealed similar trends in terms of Belize's forest cover. Both studies indicate that each year, 0.6% of Belize's forest cover is lost, translating to the clearing of an average of 10,050 hectares (24,835 acres) each year. The USAID-supported SERVIR study by CATHALAC, NASA, and the MNRE also showed that Belize's protected areas have been extremely effective in protecting the country's forests.
Dolor (pain) Calor (heat) Rubor (redness) of the skin Tumor (swelling) Functio laesa (loss of function) The first four (classical signs) were described by Celsus (c. 30 BC–38 AD). Pain is due to the release of chemicals such as bradykinin and histamine that stimulate nerve endings. Heat and redness are due to increased blood flow at body core temperature to the inflamed site. Swelling is caused by accumulation of fluid. The fifth sign, loss of function, is believed to have been added later by Galen, Thomas Sydenham or Rudolf Virchow. Examples of loss of function include pain that inhibits mobility, severe swelling that prevents movement, having a worse sense of smell during a cold, or having difficulty breathing when bronchitis is present. Loss of function has multiple causes. Chronic inflammation often presents symptoms such as:
Sources: en.wikipedia.org
Methylene blue is a monoamine oxidase inhibitor (MAOI) and, if infused intravenously at doses exceeding 5 mg/kg, may result in serotonin syndrome if combined with any selective serotonin reuptake inhibitors (SSRIs) or other serotonergic drugs (e.g., duloxetine, sibutramine, venlafaxine, clomipramine, imipramine). It causes hemolytic anemia in carriers of the G6PD enzymatic deficiency (favism). The actual degree of this danger is a subject of controversy as the association was made based on very few cases. A 2018 meta-analysis on clinical trials against malaria in Africa, where the moderate A minus type of G6PD deficiency is prevalent, shows no association between MB and hemolysis in such patients. There was, however, a clinically insignificant reduction in hemoglobin.
== Other epitope-tag combinations == The principle of tandem-affinity purification of multiprotein complexes is not limited to the combination of CBP and Protein A tags used in the original work by Rigaut et al. (1999). For example, the combination of FLAG- and HA-tags has been used since 2000 by the group of Nakatani to purify numerous protein complexes from mammalian cells. Many other tag combinations have been proposed since the TAP principle was published.
=== MBT/CBT index === The methylation of branched tetraethers (MBT) and cyclization of branched tetraethers (CBT) indices relate abundances and distributions of bacterially-produced brGDGTs to relative changes in soil pH and mean annual air temperature. Further research is needed to assess seasonal bias, appropriate calibration protocols, and whether the brGDGT distributions record air or soil temperature.
=== Gene-first === The gene-first hypothesis proposes that the first living systems were self-replicating informational molecules, most likely RNA, capable of both storing genetic information and catalyzing chemical reactions. Under this model, simple self-replicating molecules would evolve under selective pressures into increasingly complex organisms. A key advantage of the gene-first hypothesis is that a single molecule capable of template-directed replication can evolve readily if modifications breed true, whereas metabolic networks are fundamentally resistant to evolutionary change. An autocatalytic network is a set of chemical reactions where the products of some reactions act as catalysts to accelerate other reactions in the same network. In simpler terms, chemicals in the network help each other form more chemicals, creating a self-sustaining and self-replicating system. A common challenge in metabolism-first origin-of-life theories is that chemical networks without genes tend to resist change. Imagine a system where one chemical (A) helps make a second chemical (B), and this second chemical (B) helps make more of the first (A). This creates a self-replicating loop but is hard to evolve because even if a better version of the first chemical (A') appears, the system only makes the original kind (B), not the improved one (B'). For this system to evolve, the better first (A`) chemical would also need to help make a better second chemical (B'), which then helps make more of the better first chemical (A'), a very unlikely chain.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.